Learning Objectives

At the conclusion of this session, the participant should be able to:

• explain the meaning and clinical impact of the "TORCH" prenatal infections.
• discuss the epidemiology of the highlighted prenatal infections, including prevalence, transmission routes, and risk of transmission based on gestational time.
• summarize the challenges associated with the evaluation and treatment of the highlighted prenatal infections.
• describe the current pharmacotherapy and the research associated with novel potential treatments used for the highlighted prenatal infections.

Speaker:

Kimberly Miller, Pharm.D., Staff, Geisinger Commonwealth School of Medicine - nothing to disclose. 

Moderator:

Eric Wright, PharmD, MPH, Staff, Geisinger - nothing to disclose.